Mast cell stabilization and anti-histamine effects of olopatadine ophthalmic solution

A review of pre-clinical and clinical research

Lanny J. Rosenwasser, Terrence O'Brien, Jonathan Weyne

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Background: Histamine receptor activation and degranulation of mast cells are the mechanisms by which the ocular itching, hyperemia, chemosis, eyelid swelling, and tearing of seasonal allergic conjunctivitis are induced. Some of the topical solutions available as anti-allergy therapies are intended to interfere with these mechanisms, and the body of research regarding the capabilities of these therapeutic molecules continues to expand. Objective: To review the currently available literature regarding one topical ophthalmic anti-allergy agent, olopatadine (Patanol*), and its anti-histaminic and mast cell stabilizing actions, both in pre-clinical and clinical settings. Design and methods: Relevant research of laboratory, animal model, and clinical trial studies performed using olopatadine was reviewed. MEDLINE literature searches were conducted and supplemented by additional reports which furthered relevant discussion or were necessary to verify the information resulting from original searches. Results: Olopatadine demonstrates unique properties both pre-clinically and clinically which differentiate it from other therapeutic molecules in its class of dual action mast cell stabilizer/anti-histamine. Its non-perturbation of cell membranes, human conjunctival mast cell stabilization in vivo and in vitro, and superior efficacy as compared to other topical anti-allergic medications including mast cell stabilizers, anti-histamines, and dual action agents, all contribute to olopatadine's profile. Conclusions: Peer-reviewed literature suggests that olopatadine is clinically superior to the other anti-allergic molecules because of its strong anti-histaminic qualities and its unique ocular mast cell stabilizing properties.

Original languageEnglish
Pages (from-to)1377-1387
Number of pages11
JournalCurrent Medical Research and Opinion
Volume21
Issue number9
DOIs
StatePublished - Sep 1 2005
Externally publishedYes

Fingerprint

Histamine Agents
Ophthalmic Solutions
Mast Cells
Research
Anti-Allergic Agents
Histamine
Hypersensitivity
Allergic Conjunctivitis
Histamine Receptors
Hyperemia
Eyelids
Pruritus
MEDLINE
Olopatadine Hydrochloride
Therapeutics
Animal Models
Cell Membrane
Clinical Trials

Keywords

  • Anti-histamines
  • Mast cell stabilizer
  • Ocular allergy
  • Olopatadine

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Mast cell stabilization and anti-histamine effects of olopatadine ophthalmic solution : A review of pre-clinical and clinical research. / Rosenwasser, Lanny J.; O'Brien, Terrence; Weyne, Jonathan.

In: Current Medical Research and Opinion, Vol. 21, No. 9, 01.09.2005, p. 1377-1387.

Research output: Contribution to journalArticle

@article{162b8c3dd38144a8bf87f410e55dbc34,
title = "Mast cell stabilization and anti-histamine effects of olopatadine ophthalmic solution: A review of pre-clinical and clinical research",
abstract = "Background: Histamine receptor activation and degranulation of mast cells are the mechanisms by which the ocular itching, hyperemia, chemosis, eyelid swelling, and tearing of seasonal allergic conjunctivitis are induced. Some of the topical solutions available as anti-allergy therapies are intended to interfere with these mechanisms, and the body of research regarding the capabilities of these therapeutic molecules continues to expand. Objective: To review the currently available literature regarding one topical ophthalmic anti-allergy agent, olopatadine (Patanol*), and its anti-histaminic and mast cell stabilizing actions, both in pre-clinical and clinical settings. Design and methods: Relevant research of laboratory, animal model, and clinical trial studies performed using olopatadine was reviewed. MEDLINE literature searches were conducted and supplemented by additional reports which furthered relevant discussion or were necessary to verify the information resulting from original searches. Results: Olopatadine demonstrates unique properties both pre-clinically and clinically which differentiate it from other therapeutic molecules in its class of dual action mast cell stabilizer/anti-histamine. Its non-perturbation of cell membranes, human conjunctival mast cell stabilization in vivo and in vitro, and superior efficacy as compared to other topical anti-allergic medications including mast cell stabilizers, anti-histamines, and dual action agents, all contribute to olopatadine's profile. Conclusions: Peer-reviewed literature suggests that olopatadine is clinically superior to the other anti-allergic molecules because of its strong anti-histaminic qualities and its unique ocular mast cell stabilizing properties.",
keywords = "Anti-histamines, Mast cell stabilizer, Ocular allergy, Olopatadine",
author = "Rosenwasser, {Lanny J.} and Terrence O'Brien and Jonathan Weyne",
year = "2005",
month = "9",
day = "1",
doi = "10.1185/030079905X56547",
language = "English",
volume = "21",
pages = "1377--1387",
journal = "Current Medical Research and Opinion",
issn = "0300-7995",
publisher = "Informa Healthcare",
number = "9",

}

TY - JOUR

T1 - Mast cell stabilization and anti-histamine effects of olopatadine ophthalmic solution

T2 - A review of pre-clinical and clinical research

AU - Rosenwasser, Lanny J.

AU - O'Brien, Terrence

AU - Weyne, Jonathan

PY - 2005/9/1

Y1 - 2005/9/1

N2 - Background: Histamine receptor activation and degranulation of mast cells are the mechanisms by which the ocular itching, hyperemia, chemosis, eyelid swelling, and tearing of seasonal allergic conjunctivitis are induced. Some of the topical solutions available as anti-allergy therapies are intended to interfere with these mechanisms, and the body of research regarding the capabilities of these therapeutic molecules continues to expand. Objective: To review the currently available literature regarding one topical ophthalmic anti-allergy agent, olopatadine (Patanol*), and its anti-histaminic and mast cell stabilizing actions, both in pre-clinical and clinical settings. Design and methods: Relevant research of laboratory, animal model, and clinical trial studies performed using olopatadine was reviewed. MEDLINE literature searches were conducted and supplemented by additional reports which furthered relevant discussion or were necessary to verify the information resulting from original searches. Results: Olopatadine demonstrates unique properties both pre-clinically and clinically which differentiate it from other therapeutic molecules in its class of dual action mast cell stabilizer/anti-histamine. Its non-perturbation of cell membranes, human conjunctival mast cell stabilization in vivo and in vitro, and superior efficacy as compared to other topical anti-allergic medications including mast cell stabilizers, anti-histamines, and dual action agents, all contribute to olopatadine's profile. Conclusions: Peer-reviewed literature suggests that olopatadine is clinically superior to the other anti-allergic molecules because of its strong anti-histaminic qualities and its unique ocular mast cell stabilizing properties.

AB - Background: Histamine receptor activation and degranulation of mast cells are the mechanisms by which the ocular itching, hyperemia, chemosis, eyelid swelling, and tearing of seasonal allergic conjunctivitis are induced. Some of the topical solutions available as anti-allergy therapies are intended to interfere with these mechanisms, and the body of research regarding the capabilities of these therapeutic molecules continues to expand. Objective: To review the currently available literature regarding one topical ophthalmic anti-allergy agent, olopatadine (Patanol*), and its anti-histaminic and mast cell stabilizing actions, both in pre-clinical and clinical settings. Design and methods: Relevant research of laboratory, animal model, and clinical trial studies performed using olopatadine was reviewed. MEDLINE literature searches were conducted and supplemented by additional reports which furthered relevant discussion or were necessary to verify the information resulting from original searches. Results: Olopatadine demonstrates unique properties both pre-clinically and clinically which differentiate it from other therapeutic molecules in its class of dual action mast cell stabilizer/anti-histamine. Its non-perturbation of cell membranes, human conjunctival mast cell stabilization in vivo and in vitro, and superior efficacy as compared to other topical anti-allergic medications including mast cell stabilizers, anti-histamines, and dual action agents, all contribute to olopatadine's profile. Conclusions: Peer-reviewed literature suggests that olopatadine is clinically superior to the other anti-allergic molecules because of its strong anti-histaminic qualities and its unique ocular mast cell stabilizing properties.

KW - Anti-histamines

KW - Mast cell stabilizer

KW - Ocular allergy

KW - Olopatadine

UR - http://www.scopus.com/inward/record.url?scp=25444463056&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=25444463056&partnerID=8YFLogxK

U2 - 10.1185/030079905X56547

DO - 10.1185/030079905X56547

M3 - Article

VL - 21

SP - 1377

EP - 1387

JO - Current Medical Research and Opinion

JF - Current Medical Research and Opinion

SN - 0300-7995

IS - 9

ER -